| CORPORATIONS |
CORPORATIONS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| DISTRIBUTOR-CUSTOMERS |
DISTRIBUTOR-CUSTOMERS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| INDEPENDENT-LABORATORIES |
INDEPENDENT-LABORATORIES |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| LARGE-HOSPITAL-SYSTEMS |
LARGE-HOSPITAL-SYSTEMS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| PUBLIC-AND-PRIVATE-INSTITUTIONS |
PUBLIC-AND-PRIVATE-INSTITUTIONS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| RESEARCH-ORGANIZATIONS |
RESEARCH-ORGANIZATIONS |
90%
|
Our Company has two types of customers: (i) direct end user customers, which may include research organizations, corporations, independent laboratories, large hospital systems and public and private … |
| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from VRAX graph: n and T-cell exhaustion. Participants in the in-vitro diagnostics industry include biotechnology companies, establishe… |
| ABT |
Abbott Laboratories |
72%
|
n and T-cell exhaustion. Participants in the in-vitro diagnostics industry include biotechnology companies, established pharmaceutical companies, and other in-vitro diagnostics companies. Many of our… |
| NCNA |
NuCana plc |
72%
|
regular healthcare consulting are still hindrances in some regions, especially third-world countries, which impedes the growth of the IVD market. Key Supplier Relationships We source our suppliers th… |
| NCNA |
NuCana plc |
72%
|
Reciprocal relationship from NCNA graph: Reciprocal relationship from VRAX graph: Reciprocal relationship from NCNA graph: Reciprocal relationship from VRAX graph: regular healthcare consulting are s… |
| QGEN |
Qiagen N.V. |
72%
|
n and T-cell exhaustion. Participants in the in-vitro diagnostics industry include biotechnology companies, established pharmaceutical companies, and other in-vitro diagnostics companies. Many of our… |
| QGEN |
Qiagen N.V. |
72%
|
Reciprocal relationship from QGEN graph: Reciprocal relationship from VRAX graph: Reciprocal relationship from QGEN graph: Reciprocal relationship from VRAX graph: Reciprocal relationship from QGEN g… |
| ADPT-ROCHE-HOLDING-AG |
ADPT-ROCHE-HOLDING-AG |
62%
|
n and T cell exhaustion. Participants in the in-vitro diagnostics industry include biotechnology companies, established pharmaceutical companies, and other in-vitro diagnostics companies. Many of our… |
| AG-PROFESSIONAL-CARDIAC-INC |
AG-PROFESSIONAL-CARDIAC-INC |
62%
|
en Receptor T cell (CAR-T) therapies, Myloid, Encephalomyelitis (ME) and post viral syndromes. This versatility will position ViraxImmune as a comprehensive platform capable of potentially addressing… |
| BOUSTEAD-SECURITIES-LLC |
BOUSTEAD-SECURITIES-LLC |
62%
|
e of business. Liquidity is the ability of a company to fund its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. At March 31, 2025, the Company had … |
| MEDICAL-DEVICE-COMPANY-LIMITED |
MEDICAL-DEVICE-COMPANY-LIMITED |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
security of our information systems and the data maintained in those systems, it is possible that our safety and security measures will not prevent the systems’ improper functioning or damage or the … |
| NATURAL-SOURCE-GROUP |
NATURAL-SOURCE-GROUP |
62%
|
. This lease was subsequently modified in August 2023 and November 2023 to include additional rooms at BioCity. Lease expense for the year ended March 31, 2024 was GBP 27,521 . The annual rent as of … |
| NATURAL-SOURCE-GROUP-PTE-LIMITED |
NATURAL-SOURCE-GROUP-PTE-LIMITED |
62%
|
regular healthcare consulting are still hindrances in some regions, especially third-world countries, which impedes the growth of the IVD market. Key Supplier Relationships We source our suppliers th… |
| QGEN-ADAPTIVE-BIOTECHNOLOGIES-CORPORATION |
QGEN-ADAPTIVE-BIOTECHNOLOGIES-CORPORATION |
62%
|
n and T cell exhaustion. Participants in the in-vitro diagnostics industry include biotechnology companies, established pharmaceutical companies, and other in-vitro diagnostics companies. Many of our… |
| SHANGHAI-BIOTECHNOLOGY-DEVICES-LIMITED |
SHANGHAI-BIOTECHNOLOGY-DEVICES-LIMITED |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
| SHANGHAI-BIOTECHNOLOGY-DEVICES-LTD |
SHANGHAI-BIOTECHNOLOGY-DEVICES-LTD |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
| SHANGHAI-XITU-CONSULTING-CO-LIMITED |
SHANGHAI-XITU-CONSULTING-CO-LIMITED |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
| UK-LIMITED |
UK-LIMITED |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
| VIRAX-BIOLABS-LIMITED |
VIRAX-BIOLABS-LIMITED |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
| VIRAX-IMMUNE-T-CELL-MEDICAL-DEVICE-COMPANY-LIMIT |
VIRAX-IMMUNE-T-CELL-MEDICAL-DEVICE-COMPANY-LIMIT |
62%
|
ter established credibility and market reputations, and broader service and product offerings; • greater financial, technical, marketing and other resources, which may allow them to pursue enhanced d… |
